Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Advanced Breast Cancer
Interventions: DRUG: Everolimus 10 mg|DRUG: CDK4/6 Inhibitor SHR6390|DRUG: Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors
Sponsor: Fudan University